Nabsys 2.0, LLC

PROVIDENCE – November 05, 2026 -- Electronic Genome Mapping (EGM) detected every abnormality identified by standard cytogenetic testing in an initial study, according to researchers from Augusta University and The University of Texas MD Anderson Cancer Center. They will present the findings at the Association for Molecular Pathology (AMP) 2026 Annual Meeting, November 10-14 in Seattle, Nabsys 2.0, LLC said.

Augusta and MD Anderson pathologists present EGM data on November 13

Ravindra Kolhe, M.D., Ph.D., Professor and Chair of Pathology at Augusta University, and Rashmi Kanagal-Shamanna, M.D., Professor of Hematopathology and Molecular Diagnostics at MD Anderson, will present at the Innovation Spotlight Session (stage 1). The slot runs 9:30-10:00 a.m. PT on Friday, November 13. The talk is titled "Electronic Genome Mapping for Structural Variant Detection: Implications for Advancing Clinical Research in Heme Malignancies."

Providence – October 16, 2026 -- Nabsys 2.0, LLC has released RepX, a cloud-based pipeline that can analyze up to 23 disease-associated repeat expansion loci in a single, low-cost run, according to the company.

RepX is available through the Nabsys Navigator cloud platform. It processes Electronic Genome Mapping (EGM) data generated on the OhmX Platform.

EGM reads single ultra-long DNA molecules without amplification or ligation

Repeat expansions are linked to numerous inherited disorders but remain difficult to characterize. EGM analyzes individual ultra-long DNA molecules without amplification or ligation, which avoids biases tied to those processes. Researchers can examine the distribution of expansion sizes and investigate repeat instability within each allele.

Providence, R.I. – September 21, 2026 -- Nabsys 2.0, LLC has published the first study combining CRISPR/Cas9 with its proprietary Electronic Genome Mapping (EGM) technology, demonstrating a method to both evaluate CRISPR/Cas9 activity and direct EGM to target specific genomic regions rather than only genome-wide analysis.

The preprint, titled 'CRISPR/Cas9 Optimization Using Electronic Genome Mapping: Potential Role for Studying Human Genetic Disease,' was led by John F. Thompson, Ph.D., Principal Application Scientist at Nabsys, and posted on bioRxiv.